1 completed, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Malignant Neoplasms: new trials by email Literature Review of Malignant Neoplasms trials Research Report on Malignant Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2026-03-23 | 2026-10-21 |
| Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases Naderin, Standard Therapy - Malignant Neoplasms, Tuberculosis (TB) | Phase 2 / Phase 3 | Completed | MIPO Clinic | 75 | 2013-05-15 | 2026-06-30 |
Neoplasms (2) · Hepatitis C (1) · Neutropenia (1) · Tuberculosis (1) · von Hippel-Lindau Disease (1)
Abnormalities, Multiple (1) · Actinomycetales Infections (1) · Agranulocytosis (1) · Angiomatosis (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Blood-Borne Infections (1) · Cardiovascular Diseases (1) · Ciliopathies (1) · Communicable Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cytopenia (1) · Digestive System Diseases (1) · Flaviviridae Infections (1)
Nivolumab (1) · Standard of Care (1) · belzutifan (1) · cabozantinib (1) · lenvatinib (1) · sodium nucleinate (1)
MIPO Clinic (1) · Merck Sharp & Dohme LLC (1)
Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · Israel (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1)
2025 (1)